Cambridge, Mass., September 3, 2026 — Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in the HKEX Tech 100 Index, following the methodology enhancements to broaden the exposure to “emerging technology trends, including opportunities across the AI value chain”, announced on 18 August 2026. All changes will be implemented after the market close on 11 September 2026 (Friday) and take effect on 14 September 2026 (Monday).

- KAIST and Samsung Electronics have developed a new, long-lasting catalyst based on ‘entropy stabilization,’ a principle in which mixing multiple metal atoms together actually stabilizes the catalyst’s structure

- Boosts CF₄ decomposition performance 2.3 times over conventional catalysts — retains 92% activity even after 150 hours at 800°C

- Tracks the migration pathway of oxygen atoms to provide the first experimental evidence for a CF₄ decomposition mechanism that had previously only been proposed in theory

Roughly 10 percent of the American population lives with a neurodevelopmental condition, including autism spectrum disorders, ADHD, learning disorders, auditory and visual processing disorders, and more. Salk researchers uncover link between severe maternal illness during pregnancy and elevated risk of neurodevelopmental disorders in mice. Findings show maternal immune activation, as occurs during illness, leads to widespread epigenetic changes and altered frontal cortex in offspring.